Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group
Rhea-AI Summary
Annovis (NYSE: ANVS) will present at the 2025 Annual Meeting of the Parkinson Study Group in San Diego, Dec 4-6, 2025.
The company will present Phase 3 Parkinson's disease biomarker data showing that patients with amyloid co-pathology experienced greater cognitive decline that was counteracted and reversed by buntanetap; buntanetap also reduced tau biomarkers. The poster includes a cross-study comparison of completed trials and highlights that patients with amyloid pathology show the largest cognitive gains.
Presentation: Amyloid co-pathology, cognitive decline, and improvement in buntanetap-treated Parkinson’s disease dementia patients by Maria Maccecchini, Ph.D., on Dec 5 at 6:15 p.m. PST; data will be posted on the company website after the meeting.
Positive
- None.
Negative
- None.
News Market Reaction – ANVS
In the Dec 3 session, ANVS gained 5.44%, reflecting a notable positive market reaction. Argus tracked a peak move of +8.0% during that session. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 03 | Conference presentation | Positive | +5.4% | PSG meeting presentation on Phase 3 PD biomarker and cognition data. |
| Nov 24 | Conference presentations | Positive | +7.9% | Two CTAD 2025 talks highlighting buntanetap biomarker and cognition data. |
| Nov 18 | Regulatory meeting | Positive | +11.2% | FDA Type C meeting scheduled and reaffirmed alignment on Phase 3 AD trial. |
| Nov 17 | Clinical data update | Positive | +29.5% | Phase 3 PD data showing halted cognitive decline and biomarker improvements. |
| Nov 12 | Earnings and update | Neutral | +15.2% | Q3 2025 results plus progress on Phase 3 AD sites and biomarker data. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news—mainly clinical and conference-related updates—has often coincided with positive next-day price moves, suggesting investors have reacted favorably to buntanetap progress and data disclosures.
Over the past month, Annovis has repeatedly highlighted buntanetap’s clinical progress, including Phase 3 Parkinson’s biomarker data and FDA interactions. News on Nov 17 and Nov 24 emphasized cognitive benefits and amyloid co-pathology findings, followed by CTAD 2025 presentation plans. The Nov 18 FDA meeting update and Nov 12 Q3 2025 results also drew positive reactions. Today’s PSG presentation announcement extends this thread by spotlighting cross-study cognitive outcomes in Parkinson’s and Alzheimer’s populations.
Key Terms
phase 3 medical
amyloid co-pathology medical
tau biomarkers medical
translational inhibitor medical
biomarker-confirmed medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
MALVERN, Pa., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it will present at the 2025 Annual Meeting of the Parkinson Study Group (PSG), taking place December 4-6, 2025 in San Diego, California.
The presentation builds on momentum from the Company’s recent Phase 3 PD biomarker data, showing that patients with amyloid co-pathology experience more pronounced cognitive decline, which is counteracted and reversed by buntanetap. In the same patients, buntanetap also reduces tau biomarkers, which are known to increase with disease severity.
The presentation will also debut a cross-study comparison of the completed trials, providing the most comprehensive look yet at cognitive outcomes across all tested indications by Annovis and highlighting the population that benefits most – patients with amyloid pathology. In both Parkinson’s and Alzheimer’s, individuals with biomarker-confirmed presence of amyloid experience the greatest cognitive gain following buntanetap. These findings further validate the drug’s mechanism as a translational inhibitor of neurotoxic aggregating proteins and support the Company’s next strategic steps.
Presentation details:
- Title: Amyloid co-pathology, cognitive decline, and improvement in buntanetap-treated Parkinson’s disease dementia patients
- Presenter: Maria Maccecchini, Ph.D., President and CEO
- Format: Poster guided tour
- Time of presentation: December 5, 6:15 p.m. PST
The data presented at the meeting will be posted on the Company's website following the conference.
The PSG Annual Meeting brings together leading investigators, coordinators, trainees, advocates, and allied stakeholders to advance collaborative research and showcase the latest advances and best practices in PD.
About Annovis
Headquartered in Malvern, Pennsylvania, Annovis is dedicated to addressing neurodegeneration in diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). The Company is committed to developing innovative therapies that improve patient outcomes and quality of life. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.
Investor Alerts
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at https://www.annovisbio.com/email-alerts.
Forward-Looking Statements
This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.
Contact Information:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com
Investor Contact:
Alexander Morin, Ph.D.
Director, Strategic Communications
Annovis Bio
ir@annovisbio.com
